The FDA cleared an investigational new drug application for AVZO-1418/DB-1418, and a phase 1/2 trial in advanced solid tumors ...

POLB 001 has been granted FDA orphan drug designation as a preventative therapy for cytokine release syndrome caused by ...

Kat M. Aguilar, MPH, discussed findings on social determinants of health and cancer mortality and their practical ...

Naomi Haas, MD, discusses the 5-year follow-up of the KEYNOTE-564 study being presented at the 2025 ASCO Annual Meeting.

A panelist discusses how axatilimab demonstrated efficacy in a heavily pretreated patient population with predominantly severe chronic graft-vs-host disease (cGVHD) in the AGAVE-201 trial, with ...

A panelist discusses how axatilimab is particularly effective for patients with bronchiolitis obliterans syndrome, showing response rates of almost 50% with 20% complete responses, and offers the ...

Dong Chen, MD, PhD, discusses how AI has changed the landscape for genomic testing and patient management. AI has truly revolutionized healthcare, profoundly enhancing both patient management and the ...

Patients with BRCA-altered uterine leiomyosarcoma treated with PARP inhibitors demonstrated encouraging outcomes.

As the oncology community prepares for the 2025 American Society of Clinical Oncology Annual Meeting, anticipation is running ...

Prof Martin Dreyling discusses the unmet needs in MCL and the potential next lines of research on the BTK inhibitor acalabrutinib.

In an interview, Aditya Shreenivas, MD, MS, discussed the approval of penpulimab in nasopharyngeal carcinoma and the study ...

In an interview, Arvind Bussetty, MD, and Arvind Trindade, MD, delved into the rising rates of gastrointestinal cancers among younger patients.